This brief summarizes IQVIA insights shared at the 2025 China CNS Innovation Forum, focusing on emerging trends and challenges in central nervous system drug development. It reviews global and China-specific pipelines for antipsychotic therapies, highlighting unmet needs in schizophrenia and depression despite rising disease burden. The document discusses innovation slowdowns, high trial failure rates, and the need for new dopaminergic and non-dopaminergic targets. It also presents findings on factors influencing clinical trial participation and placebo effects among Chinese patients with depression, emphasizing patient education, trial design optimization, and objective endpoints. IQVIA underscores patient-centric, data-driven approaches to accelerate CNS innovation and improve outcomes.

Join for free to read